×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Skin Cancer

Brielle Urciuoli
Researchers noted that melanoma diagnosis and treatment did not cause many women to put off becoming pregnant.
Kristie L. Kahl
Individuals diagnosed with a high frequency of basal cell carcinomas, a common type of skin cancer, may be at an increased for developing an unrelated cancer, highlighting the need for additional clinical screening.
MIKE HENNESSY, SR.
Research continues to drive the oncology field.
Kristie L. Kahl
Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.
ARLENE WEINTRAUB
Clinical trials seek to discover new ways to attack the disease, limit metastasis and prevent recurrence.
Felicia Mitchell
Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.
Jessica Skarzynski
Understanding how melanoma spreads can lead to better outcomes. That's what researchers at UCSF aimed to do.
Brielle Urciuoli
July is UV Safety Awareness Month. See three tips on how to protect yourself from harmful UV rays, which are the leading cause of skin cancer.
Brielle Urciuoli
While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.
 
Jason M. Broderick
The FDA has approved the combination of the BRAF inhibitor Braftovi (encorafenib) and the MEK inhibitor Mektovi (binimetinib) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other